Drug intelligence / Profile preview

canagliflozin + dapagliflozin + empagliflozin + ipragliflozin

Development stage: Unknown
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of four sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by preventing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and reduced blood glucose levels. These medications are primarily used for treating type 2 diabetes and have shown cardiovascular and renal protective effects. The combination of multiple SGLT2 inhibitors is not a standard clinical practice, as these drugs share the same mechanism of action.

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on canagliflozin + dapagliflozin + empagliflozin + ipragliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on canagliflozin + dapagliflozin + empagliflozin + ipragliflozin.

Explore the full profile